
What We're Reading: Aetna Deal Drives CVS Profit; Peanut Allergy Treatment; Climate Change Education in Med School
On Wednesday, CVS announced strong second-quarter profits; DBV Technologies has submitted its Biologics License Application to the FDA for its treatment for peanut allergy; doctors, health organizations, and students are pushing for medical education to include climate change.
CVS Beats Profit Estimates, Thanks in Part to Aetna Deal
CVS’ deal with Aetna is beginning to pay off, according to the pharmacy chain’s second-quarter profit, which beat expectations. CVS on Wednesday reported $1.94 billion in profit. The company raised its full-year adjustment earnings forecast to $6.89 to $7.00 per share, up from $6.75 to $6.90. According to
DBV Technologies Submits Application for Peanut Allergy Treatment
DBV Technologies
Doctors, Health Organizations Push for Climate Change Education in Med School
Backed by the American Medical Association, there is a movement from doctors, health organizations, and students for medical education to include climate change. The groups argue that physicians and other healthcare workers need to prepare for the risks association with rising global temperatures, reported
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.